Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma.
Hayashi M, Guida E, Inokawa Y, Goldberg R, Reis LO, Ooki A, Pilli M, Sadhukhan P, Woo J, Choi W, Izumchenko E, Gonzalez LM, Marchionni L, Zhavoronkov A, Brait M, Bivalacqua T, Baras A, Netto GJ, Koch W, Singh A, Hoque MO. Hayashi M, et al. Among authors: choi w. Sci Signal. 2020 Aug 18;13(645):eaba0443. doi: 10.1126/scisignal.aba0443. Sci Signal. 2020. PMID: 32817372
Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.
Kates M, Nirschl TR, Baras AS, Sopko NA, Hahn NM, Su X, Zhang J, Kochel CM, Choi W, McConkey DJ, Drake CG, Bivalacqua TJ. Kates M, et al. Among authors: choi w. Eur Urol Oncol. 2021 Feb;4(1):117-120. doi: 10.1016/j.euo.2019.01.017. Epub 2019 Feb 26. Eur Urol Oncol. 2021. PMID: 31411999
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.
Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ. Kates M, et al. Among authors: choi w. Clin Cancer Res. 2020 Feb 15;26(4):882-891. doi: 10.1158/1078-0432.CCR-19-1920. Epub 2019 Nov 11. Clin Cancer Res. 2020. PMID: 31712383
Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Becker REN, Meyer AR, Brant A, Reese AC, Biles MJ, Harris KT, Netto G, Matoso A, Hoffman-Censits J, Hahn NM, Choi W, McConkey D, Pierorazio PM, Johnson MH, Schoenberg MP, Kates MR, Baras A, Bivalacqua TJ. Becker REN, et al. Among authors: choi w. Eur Urol. 2021 Mar;79(3):364-371. doi: 10.1016/j.eururo.2020.07.016. Epub 2020 Aug 17. Eur Urol. 2021. PMID: 32814637
Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome.
Lombardo KA, Murati Amador B, Parimi V, Hoffman-Censits J, Choi W, Hahn NM, Kates M, Bivalacqua TJ, McConkey D, Hoque MO, Matoso A. Lombardo KA, et al. Among authors: choi w. Appl Immunohistochem Mol Morphol. 2021 Feb 1;29(2):127-135. doi: 10.1097/PAI.0000000000000872. Appl Immunohistochem Mol Morphol. 2021. PMID: 32858539 Free PMC article.
Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience.
Hoffman-Censits J, Choi W, Bivalacqua TJ, Pierorazio P, Kates M, Lombardo K, Parini V, McConkey D, Trabulsi EJ, Hahn N, Matoso A. Hoffman-Censits J, et al. Among authors: choi w. Clin Genitourin Cancer. 2021 Apr;19(2):176-181. doi: 10.1016/j.clgc.2020.10.009. Epub 2020 Nov 12. Clin Genitourin Cancer. 2021. PMID: 33358150 Free PMC article. No abstract available.
Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes.
Hoffman-Censits JH, Lombardo KA, Parimi V, Kamanda S, Choi W, Hahn NM, McConkey DJ, McGuire BM, Bivalacqua TJ, Kates M, Matoso A. Hoffman-Censits JH, et al. Among authors: choi w. Appl Immunohistochem Mol Morphol. 2021 Sep 1;29(8):619-625. doi: 10.1097/PAI.0000000000000938. Appl Immunohistochem Mol Morphol. 2021. PMID: 33901032 Free PMC article.
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, Kates MR, Bivalacqua TJ, Tran PT, Song DY, Baras AS, Matoso A, Choi W, Smith KN, Pardoll DM, Marchionni L, McGuire B, Grace Phelan M, Johnson BA 3rd, O'Neal T, McConkey DJ, Rose TL, Bjurlin M, Lim EA, Drake CG, McKiernan JM, Deutsch I, Anderson CB, Lamm DL, Geynisman DM, Plimack ER, Hallman MA, Horwitz EM, Al-Saleem E, Chen DYT, Greenberg RE, Kutikov A, Guo G, Masterson TA, Adra N, Kaimakliotis HZ. Hahn NM, et al. Among authors: choi w. Eur Urol. 2023 Jun;83(6):486-494. doi: 10.1016/j.eururo.2023.01.017. Epub 2023 Jan 28. Eur Urol. 2023. PMID: 36717286 Clinical Trial.
6,218 results